COVID-19 UPDATE: All elective surgeries and procedures have been postponed. See our visitor policy. If you think you have symptoms, call your doctor for a video visit before going to one of our locations. For more information, visit our COVID-19 Information Center or call our Hotline: 1-844-444-CV19 (1-844-444-2819).

AVISO SOBRE COVID-19: Todas las cirugías y procedimientos electivos han sido retrasados. Vea nuestra normas para visitas. Si cree que tiene síntomas, llame a su médico para una visita por vídeo antes de acudir en persona a uno de nuestros centros. Si desea más información, por favor visite nuestro Centro de Información del COVID-19 o llame a nuestra Línea Directa: 1-844-444-CV19 (1-844-444-2819).

Meet Our Urologists

2020 Departmental Highlights

The Urology research team at Montefiore and Einstein was ranked 13th in total 2019 National Institutes of Health (NIH) funding in the field of Urology by the Blue Ridge Institute for Medical Research. Kelvin Davies, PhD, was ranked 8th as a Principal Investigator in the field of Urology. 

Guillermo Adolfo Villegas, PhD, was named a 2020-2021 Research Scholar by the American Urological Association. The AUA Research Scholar Program provides $40,000 per year for one- and two-year mentored training for clinical and postdoctoral fellows who are no more than five years beyond completing a doctorate or residency and early career investigators who are in the first five years after beginning a faculty position. Congratulations to Dr. Villegas!

Jonathan Davila, MD, PGY-3, received the 2020 Men's Health Traveling Fellowship Award from the Society for the Study of Male Reproduction (SSMR) and the Society for Sexual Medicine of North America (SMSNA). The fellowship program, which promotes mentorship between fellow and leaders in the field, aims to present residents in training with a more intensive exposure to male fertility medicine and sexual medicine. Congratulations to Dr. Davila!

Evan Kovac, MD, Assistant Professor, Urology, Montefiore and Einstein, led a groundbreaking study that could lead to less frequent prostate cancer screening, fewer unnecessary tests and onerous treatments for up to 85 percent of men. The study, which was published in JAMA Network Open, is one of the largest of its kind, (17,000 men) and examined the value of a one-time screening of PSA (prostate-specific antigen) levels to predict long-term prostate cancer risk, rather than annual screening tests.

To read Dr. Kovac’s complete study, click here.